Novo Nordisk is not resting on its laurels. Its blockbuster weight loss drug semaglutide (sold under the brand names Ozempic and Wegovy) is expected to become the world's top-selling drug franchise next year and may reach a $130 billion market in the next five years,...,Novo Nordisk is not resting on its laurels. Its blockbuster weight loss drug semaglutide (sold under the brand names Ozempic and Wegovy) is expected to become the world's top-selling drug franchise next year and may reach a $130 billion market in the next five years,...